Nasdaq exas.

EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...Nov 20, 2023 · Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Nov 4, 2023 · Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.45) EPS for the quarter, beating ...

EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

Apr 24, 2023 · Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ... Find the latest SEC Filings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ...Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001.

A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have added about 2.5% in that time frame, underperforming the S&P …Web

EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...

Find the latest on short interest for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. ... To EXAS's credit, this debt issuance has been opportunistic CV offerings, at ...Exact Sciences EXAS stock price today per share is 67.03 USD. How to purchase Exact Sciences stock? You can buy EXAS shares on the NasdaqCM exchange. Contact ...Mar 9, 2023 · On March 9, 2023, Citigroup upgraded their outlook for EXACT Sciences (NASDAQ:EXAS) from Neutral to Buy.. Analyst Price Forecast Suggests 15.57% Upside. As of March 9, 2023, the average one-year ...

The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ... Dec 4, 2023 · Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure ... Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ... Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...

Among the largest underlying components of ARKG, in trading today EXACT Sciences Corp. (Symbol: EXAS) is down about 0.3%, Ionis Pharmaceuticals Inc (Symbol: IONS) is up about 3%, and Intellia ...

EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Exact Sciences in a research report issued to clients and investors on ...Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

Dec. 1, 2023, 07:35 AM. Leerink Partners analyst Puneet Souda maintained a Buy rating on Exact Sciences ( EXAS – Research Report) yesterday and set a price target of $115.00. …Web

Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...

Exact Sciences Co. ( NASDAQ:EXAS – Get Free Report) was up 7.6% during trading on Friday . The company traded as high as $66.06 and last traded at $65.84. Approximately 1,116,388 shares changed hands during trading, a decline of 40% from the average daily volume of 1,860,572 shares. The stock had previously closed at $61.17.MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020.Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...Exact Sciences Corporation EXAS continues to make significant progress with its Cologuard test. However, the pandemic-led continued business disruption is a concern. Exact Sciences currently ...2 Nov 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. ... Nasdaq 14,158.41-100.08 (-0.70% ...The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...

3 Nov 2023 ... Exact Sciences Corporation [EXAS] Rings the Nasdaq Closing Bell | LIVE 07:29 Nasdaq MarketSite 3n #2.91% ЕХАСТ SCIENCES MAtaria Mvesday ...Find the latest on option chains for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences Corp (NASDAQ:EXAS) reported a 20% increase in total revenue for Q3 2023, reaching $628 million. The company delivered over a million test results, including a record for Cologuard ...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.10 +0.07 (+0.10%) After hours: 07:58PM...Instagram:https://instagram. dwus2030 vanguardsmall cap stocknysearca xlre Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?See the latest Exact Sciences Corp stock price (EXAS:XNAS), related news, valuation, dividends and more to help you make your investing decisions. what is a telluridemcoa stock forecast MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will ... what are best lng stocks to buy Find the latest press releases from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?Find the latest news headlines from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.